Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

LG Life Sciences132 enrolled

Overview

As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life. Patients, however, do have to tolerate daily injections of GH (rhGH).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

132

Conditions

Growth Hormone Deficiency

Interventions

sustained-release recombinant human GH (SR-rhGH)DRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women aged ≥ 20 years with diagnosed GH deficiency (caused by pituitary tumor, trauma, other pituitary disease)

Outcomes

Primary Outcomes

Safety

Adverse event

Time frame: 12 weeks

Secondary Outcomes

Efficacy

QoL-AGHDA

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.